Epidemiology Series Forecast Report on Prader-Willi Syndrome in 9 Major Markets
Prader-Willi syndrome (PWS) is a genetic disease caused by the loss of function of several genes in a particular region of chromosome 15, affecting many parts of the body. These genes provide instructions for making molecules called small nucleolar RNAs (snRNAs) which have a variety of functions, including helping to regulate other types of RNA molecules in infancy.
This report provides the current prevalent population for Prader-Willi disease across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team , several of the main symptoms and co-morbidities of Prader-Willi disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Prader-Willi disease include:
• Cardiovascular Problems
• Obstructive sleep apnoea and respiratory disorders
• Diabetes Type II
• Autism Spectrum Disorder Behavioural Characteristics
• Seizures
• Hip dysplasia
• Scoliosis
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Prader-Willi disease’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Prader-Willi disease and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Prader-Willi disease’s prevalent population.
• Identify sub-populations within Prader-Willi disease which require treatment.
• Gain an understanding of the specific markets that have the largest number Prader-Willi disease patients.
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions/ Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
o Additional data available on request
• Top-Line Prevalence for Prader-Willi Syndrome
• Main Complications and Features of Prader-Willi Patients
o Nutritional Phases of PWS
o Level of Cognitive Functions of PWS Patients
o Type of Mutation affecting chromosome 15 in PWS Patients
o Cardiovascular Problems in PWS Patients
o Respiratory Problems in PWS Patients
o Intellectual Disability and Neurological Disorders in PWS Patients
o Motor and Skeletal Impairments in PWS Patients
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
• Prevalence of PWS, total (000s)
• Prevalence of PWS, males (000s)
• Prevalence of PWS, females (000s)
• Prevalence of Nutrition Phases of PWS, total (000s)
• Prevalence of Cognitive Function of PWS patients by IQ score, total (000s)
• Prevalence of Type of Mutation of PWS patients, total (000s)
• Prevalence of Cardiovascular problems in PWS Patients, total (000s)
• Prevalence of Hypertension in PWS Patients, total (000s)
• Prevalence of Obstructive Sleep Apnoea/Respiratory problems in PWS Patients, total (000s)
• Prevalence of Autism spectrum disorder behavioural characteristics in PWS patients, total (000s)
• Prevalence of Seizures in PWS patients, total (000s)
• Prevalence of Psychotic Disorders in PWS patients, total (000s)
• Prevalence of Hip dysplasia in PWS patients, total (000s)
• Prevalence of Scoliosis in PWS patients, total (000s) total (000s)
• Abbreviations and Acronyms used in the Report
• USA Prevalence of PWS by 5-yr age cohort, males (000s)
• USA Prevalence of PWS by 5-yr age cohort, females (000s)
• France Prevalence of PWS by 5-yr age cohort, males (000s)
• France Prevalence of PWS by 5-yr age cohort, females (000s)
• Germany Prevalence of PWS by 5-yr age cohort, males (000s)
• Germany Prevalence of PWS by 5-yr age cohort, females (000s)
• Italy Prevalence of PWS by 5-yr age cohort, males (000s)
• Italy Prevalence of PWS by 5-yr age cohort, females (000s)
• Spain Prevalence of PWS by 5-yr age cohort, males (000s)
• Spain Prevalence of PWS by 5-yr age cohort, females (000s)
• United Kingdom Prevalence of PWS by 5-yr age cohort, males (000s)
• United Kingdom Prevalence of PWS by 5-yr age cohort, females (000s)
• Brazil Prevalence of PWS by 5-yr age cohort, males (000s)
• Brazil Prevalence of PWS by 5-yr age cohort, females (000s)
• Japan Prevalence of PWS by 5-yr age cohort, males (000s)
• Japan Prevalence of PWS by 5-yr age cohort, females (000s)
• India Prevalence of PWS by 5-yr age cohort, males (000s)
• India Prevalence of PWS by 5-yr age cohort, females (000s)
+1 888 709 8757
Chat With Us